Yuanming Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuanming Pan has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Zhiqi Li
Cancer Research Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China
8 shared publicationsRuijun Wang
Department of Neurosurgery, The Affiliated Hospital, Inner Mongolia Medical University
5 shared publicationsChangpeng Xie
Department of Basic Medical Sciences, Qinghai University Medical College, Xining City, China
4 shared publicationsChao Li
Department of Gastroenterology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
4 shared publicationsMeng Gu
Cancer Research Center, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
4 shared publicationsPanjian Wei
Cancer Research Center, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
4 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Springer Nature in Journal of Nanobiotechnology
Emerging roles of stem cells and exosomes in male reproductive injury: mechanisms, engineering approaches, and therapeutic potential
- 21 October 2026
- Published by Springer Nature in Journal of Nanobiotechnology
Open AccessEmerging roles of stem cells and exosomes in male reproductive injury: mechanisms, engineering approaches, and therapeutic potential
- Open Access
- 31 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1902574
Immunomodulatory functions of growth differentiation factor 15 in skin aging and inflammatory dermatoses
Growth differentiation factor 15 (GDF15) is a stress-responsive cytokine that has emerged as a pleiotropic regulator in skin biology, yet its context-dependent functions—ranging from protective to pathogenic—remain incompletely understood. This narrative review systematically synthesizes current evidence on the expression patterns, signaling mechanisms, and disease associations of GDF15 in cutaneous health and disease, with particular emphasis on melanogenesis, skin aging, photoaging, and immune-mediated dermatoses including psoriasis, systemic lupus erythematosus, and systemic sclerosis. We propose a four-parameter framework—inducing stimulus, responding cell type, exposure kinetics, and microenvironmental context—that reconciles the apparently contradictory effects of GDF15 across different skin compartments and disease phases. Mechanistically, GDF15 activates β-catenin/MITF/tyrosinase signaling in melanocytes to drive pigmentation, modulates fibroblast collagen synthesis via SMAD2/3 and SASP-associated pathways, and interfaces with the IL-23/Th17 and NF-κB axes in inflammatory skin diseases. Critically, we identify and discuss unresolved knowledge gaps, including the identity of the peripheral receptor(s) mediating GDF15’s cutaneous actions, the distinction between correlation and causation in human disease, and the therapeutic challenges posed by GDF15’s dual protective and deleterious roles. By integrating mechanistic insights with clinical observations and providing a critical assessment of current evidence levels, this review establishes GDF15 as a multi-node signaling hub in dermatology while offering a balanced roadmap for future translational research—emphasizing that the primary near-term value of GDF15 lies in biomarker development for disease monitoring and patient stratification, rather than in immediate therapeutic targeting.
- 31 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1902574
Open AccessImmunomodulatory functions of growth differentiation factor 15 in skin aging and inflammatory dermatoses
Growth differentiation factor 15 (GDF15) is a stress-responsive cytokine that has emerged as a pleiotropic regulator in skin biology, yet its context-dependent functions—ranging from protective to pathogenic—remain incompletely understood. This narrative review systematically synthesizes current evidence on the expression patterns, signaling mechanisms, and disease associations of GDF15 in cutaneous health and disease, with particular emphasis on melanogenesis, skin aging, photoaging, and immune-mediated dermatoses including psoriasis, systemic lupus erythematosus, and systemic sclerosis. We propose a four-parameter framework—inducing stimulus, responding cell type, exposure kinetics, and microenvironmental context—that reconciles the apparently contradictory effects of GDF15 across different skin compartments and disease phases. Mechanistically, GDF15 activates β-catenin/MITF/tyrosinase signaling in melanocytes to drive pigmentation, modulates fibroblast collagen synthesis via SMAD2/3 and SASP-associated pathways, and interfaces with the IL-23/Th17 and NF-κB axes in inflammatory skin diseases. Critically, we identify and discuss unresolved knowledge gaps, including the identity of the peripheral receptor(s) mediating GDF15’s cutaneous actions, the distinction between correlation and causation in human disease, and the therapeutic challenges posed by GDF15’s dual protective and deleterious roles. By integrating mechanistic insights with clinical observations and providing a critical assessment of current evidence levels, this review establishes GDF15 as a multi-node signaling hub in dermatology while offering a balanced roadmap for future translational research—emphasizing that the primary near-term value of GDF15 lies in biomarker development for disease monitoring and patient stratification, rather than in immediate therapeutic targeting.
- Open Access
- 31 July 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1843204
Correlative study of Parnassia palustris extract on orthotopic glioma suppression and gut microbiota modulation in mice
Objective: The gut microbiota is associated with brain tumor development and prognosis. Natural products are increasingly recognized for their therapeutic potential. Based on previously observed anti-glioma effects of Parnassia palustris (MHC) in vitro , this study evaluates the efficacy of its oral extract in an orthotopic glioma model and explores the correlative relationship between its antitumor activity and alterations in gut microbiota composition, without inferring causation. Methods: Four-week-old female Balb/c nude mice underwent intracranial implantation of RFP-U87 MG or U87 MG cells. Mice received intragastric administration of MHC extract (25 mg/kg every other day from day 6 to 24 post-implantation, n = 7) or PBS ( n = 7). Untreated healthy mice served as controls ( n = 6). Tumor growth was monitored via in vivo fluorescence imaging. Brain tissues and gliomas were collected for weighing, H&E, and IHC staining. Fecal samples were collected for gut microbiota analysis using Illumina high-throughput sequencing. Results: In vivo imaging and tumor weight measurements demonstrated that MHC significantly suppressed orthotopic glioma proliferation. H&E staining showed reduced tumor cell density, normalized nuclear-to-cytoplasmic ratio, and decreased nuclear atypia in the MHC group. IHC indicated that MHC inhibited the PI3K/Akt pathway, leading to decreased KI67 and increased p53 expression. MHC did not alter α -diversity but modulated the abundance of specific bacterial taxa, notably increasing Muribaculum intestinale, Bacteroides faecichinchillae , and Klebsiella oxytoca , while decreasing Lachnospiraceae bacterium A4 and Helicobacter japonicus. Compared to healthy controls, tumor-bearing mice exhibited distinct microbial profiles. Conclusion: MHC extract significantly inhibits orthotopic glioma growth and is associated with compositional changes in the gut microbiota, including enrichment of Muribaculum intestinale and Bacteroides faecichinchillae . These correlational findings indicate a potential link between microbial shifts and anti-glioma effects; however, causality remains to be established. Future studies employing fecal microbiota transplantation, antibiotic depletion, or germ-free models are required to determine whether microbiota modulation directly mediates MHC’s antitumor activity.
- 31 July 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1843204
Open AccessCorrelative study of Parnassia palustris extract on orthotopic glioma suppression and gut microbiota modulation in mice
Objective: The gut microbiota is associated with brain tumor development and prognosis. Natural products are increasingly recognized for their therapeutic potential. Based on previously observed anti-glioma effects of Parnassia palustris (MHC) in vitro , this study evaluates the efficacy of its oral extract in an orthotopic glioma model and explores the correlative relationship between its antitumor activity and alterations in gut microbiota composition, without inferring causation. Methods: Four-week-old female Balb/c nude mice underwent intracranial implantation of RFP-U87 MG or U87 MG cells. Mice received intragastric administration of MHC extract (25 mg/kg every other day from day 6 to 24 post-implantation, n = 7) or PBS ( n = 7). Untreated healthy mice served as controls ( n = 6). Tumor growth was monitored via in vivo fluorescence imaging. Brain tissues and gliomas were collected for weighing, H&E, and IHC staining. Fecal samples were collected for gut microbiota analysis using Illumina high-throughput sequencing. Results: In vivo imaging and tumor weight measurements demonstrated that MHC significantly suppressed orthotopic glioma proliferation. H&E staining showed reduced tumor cell density, normalized nuclear-to-cytoplasmic ratio, and decreased nuclear atypia in the MHC group. IHC indicated that MHC inhibited the PI3K/Akt pathway, leading to decreased KI67 and increased p53 expression. MHC did not alter α -diversity but modulated the abundance of specific bacterial taxa, notably increasing Muribaculum intestinale, Bacteroides faecichinchillae , and Klebsiella oxytoca , while decreasing Lachnospiraceae bacterium A4 and Helicobacter japonicus. Compared to healthy controls, tumor-bearing mice exhibited distinct microbial profiles. Conclusion: MHC extract significantly inhibits orthotopic glioma growth and is associated with compositional changes in the gut microbiota, including enrichment of Muribaculum intestinale and Bacteroides faecichinchillae . These correlational findings indicate a potential link between microbial shifts and anti-glioma effects; however, causality remains to be established. Future studies employing fecal microbiota transplantation, antibiotic depletion, or germ-free models are required to determine whether microbiota modulation directly mediates MHC’s antitumor activity.
- Open Access
- 29 May 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1825514
Unraveling Let-7f in oncology: a tumor suppressor with emerging clinical significance
As a major global health threat, tumors present significant clinical challenges due to their heterogeneity, metastatic potential, and therapy resistance. In recent years, non-coding RNAs, particularly microRNAs (miRNAs), have emerged as crucial players in cancer research. Among them, let-7f, a key member of the let-7 family, exhibits significant dysregulation and biological functions in various cancers. This review systematically summarizes the differential expression patterns of let-7f in common malignancies, revealing its prevalent downregulation in cancers such as lung, gastric, colorectal, breast, and glioblastoma. This downregulation is closely associated with tumor size, stage, metastatic potential, and patient prognosis. The expression of let-7f is regulated by multiple molecular mechanisms, including transcription factors (e.g., C/EBPβ), RNA-binding proteins (e.g., LIN28), ceRNA networks (e.g., FAM222A-AS1, LINC00106), and genetic polymorphisms. Regarding biological functions, let-7f inhibits tumor cell proliferation, invasion, metastasis, stemness maintenance, and metabolic reprogramming by targeting multiple oncogenes (e.g., MYH9, HMGA2, ADAMTS1, Periostin) and key signaling pathways (e.g., MAPK, Wnt, PI3K/AKT). Furthermore, let-7f is involved in modulating the tumor microenvironment, including angiogenesis, stromal cell function, and the immune milieu. At the therapeutic level, let-7f not only serves as a predictive biomarker for the efficacy of chemotherapy, radiotherapy, and endocrine therapy but also holds potential for reversing drug resistance and enhancing drug sensitivity. For diagnosis, its stable presence in body fluids like plasma and stool offers a non-invasive detection advantage, positioning it as a promising novel biomarker for various cancers. However, challenges remain, including the standardization of detection methods, optimization of delivery systems, and insufficient clinical validation. Future efforts should integrate multi-omics analyses, artificial intelligence-assisted modeling, and novel nanodelivery technologies to advance the translation of let-7f from basic research to clinical application, thereby providing new strategies for the precise diagnosis and treatment of cancer.
- 29 May 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1825514
Open AccessUnraveling Let-7f in oncology: a tumor suppressor with emerging clinical significance
As a major global health threat, tumors present significant clinical challenges due to their heterogeneity, metastatic potential, and therapy resistance. In recent years, non-coding RNAs, particularly microRNAs (miRNAs), have emerged as crucial players in cancer research. Among them, let-7f, a key member of the let-7 family, exhibits significant dysregulation and biological functions in various cancers. This review systematically summarizes the differential expression patterns of let-7f in common malignancies, revealing its prevalent downregulation in cancers such as lung, gastric, colorectal, breast, and glioblastoma. This downregulation is closely associated with tumor size, stage, metastatic potential, and patient prognosis. The expression of let-7f is regulated by multiple molecular mechanisms, including transcription factors (e.g., C/EBPβ), RNA-binding proteins (e.g., LIN28), ceRNA networks (e.g., FAM222A-AS1, LINC00106), and genetic polymorphisms. Regarding biological functions, let-7f inhibits tumor cell proliferation, invasion, metastasis, stemness maintenance, and metabolic reprogramming by targeting multiple oncogenes (e.g., MYH9, HMGA2, ADAMTS1, Periostin) and key signaling pathways (e.g., MAPK, Wnt, PI3K/AKT). Furthermore, let-7f is involved in modulating the tumor microenvironment, including angiogenesis, stromal cell function, and the immune milieu. At the therapeutic level, let-7f not only serves as a predictive biomarker for the efficacy of chemotherapy, radiotherapy, and endocrine therapy but also holds potential for reversing drug resistance and enhancing drug sensitivity. For diagnosis, its stable presence in body fluids like plasma and stool offers a non-invasive detection advantage, positioning it as a promising novel biomarker for various cancers. However, challenges remain, including the standardization of detection methods, optimization of delivery systems, and insufficient clinical validation. Future efforts should integrate multi-omics analyses, artificial intelligence-assisted modeling, and novel nanodelivery technologies to advance the translation of let-7f from basic research to clinical application, thereby providing new strategies for the precise diagnosis and treatment of cancer.
- Open Access
- 27 May 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
MicroRNA-7: a versatile player and core target in brain disorders
Objective: This article provides a systematic review of the biological characteristics, regulatory mechanisms, and roles of MicroRNA-7 (miR-7) in the nervous system, as well as explores its clinical translation potential and challenges. Methods: A review analysis integrating the progress of basic and clinical research related to miR-7. Results: Characteristics and Regulation: miR-7 is highly expressed in mammalian brain tissues, with its function finely regulated by ceRNA networks (such as ciRS-7 and lncRNA SNHG1) and epigenetic modifications, forming a multi-layer dynamic regulatory system. Mechanisms of Action: It plays multi-faceted intervention roles in protein aggregation, neuroinflammation, mitochondrial dysfunction, and tumor progression by targeting key factors such as α-synuclein, NLRP3 inflammasome, EGFR/PI3K/AKT/mTOR pathway, and mitochondrial-related proteins (e.g. VDAC1). Role in Disease: It has significant pathophysiological implications in diseases such as Parkinson’s disease, Alzheimer’s disease, ischemic stroke, cerebral hemorrhage, and glioblastoma. Translational Potential: Changes in miR-7 expression in bodily fluids (blood, cerebrospinal fluid) and extracellular vesicles demonstrate diagnostic and prognostic potential; delivery systems based on nanomedicine (e.g. liposomes, graphene oxide, AAV vectors) and their combination therapy strategies (e.g. in conjunction with chemotherapy and immunotherapy) enhance its brain targeting and therapeutic efficiency. Conclusion: miR-7 is a key regulatory molecule in brain diseases, with significant value for basic research and clinical translation. Future advancements should leverage cutting-edge technologies such as single-cell sequencing, spatial transcriptomics, and intelligent responsive nanocarriers to deepen the understanding of its regulatory networks and address challenges such as mechanism complexity, delivery system targeting, and the lack of clinical translation standards, to accelerate its transition from basic research to clinical application.
- 27 May 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessMicroRNA-7: a versatile player and core target in brain disorders
Objective: This article provides a systematic review of the biological characteristics, regulatory mechanisms, and roles of MicroRNA-7 (miR-7) in the nervous system, as well as explores its clinical translation potential and challenges. Methods: A review analysis integrating the progress of basic and clinical research related to miR-7. Results: Characteristics and Regulation: miR-7 is highly expressed in mammalian brain tissues, with its function finely regulated by ceRNA networks (such as ciRS-7 and lncRNA SNHG1) and epigenetic modifications, forming a multi-layer dynamic regulatory system. Mechanisms of Action: It plays multi-faceted intervention roles in protein aggregation, neuroinflammation, mitochondrial dysfunction, and tumor progression by targeting key factors such as α-synuclein, NLRP3 inflammasome, EGFR/PI3K/AKT/mTOR pathway, and mitochondrial-related proteins (e.g. VDAC1). Role in Disease: It has significant pathophysiological implications in diseases such as Parkinson’s disease, Alzheimer’s disease, ischemic stroke, cerebral hemorrhage, and glioblastoma. Translational Potential: Changes in miR-7 expression in bodily fluids (blood, cerebrospinal fluid) and extracellular vesicles demonstrate diagnostic and prognostic potential; delivery systems based on nanomedicine (e.g. liposomes, graphene oxide, AAV vectors) and their combination therapy strategies (e.g. in conjunction with chemotherapy and immunotherapy) enhance its brain targeting and therapeutic efficiency. Conclusion: miR-7 is a key regulatory molecule in brain diseases, with significant value for basic research and clinical translation. Future advancements should leverage cutting-edge technologies such as single-cell sequencing, spatial transcriptomics, and intelligent responsive nanocarriers to deepen the understanding of its regulatory networks and address challenges such as mechanism complexity, delivery system targeting, and the lack of clinical translation standards, to accelerate its transition from basic research to clinical application.
- Open Access
- 15 April 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Intranasal administration in modulating depressive-like behavior and reconstructing treatment paradigms through neuroinflammation and neurotrophic pathways
Intranasal administration, as a non-invasive brain-targeted delivery strategy, offers a promising approach for the treatment of central nervous system disorders, particularly depression. Traditional oral or intravenous drug delivery is often limited by the restrictive permeability of the blood-brain barrier and the hepatic first-pass effect, which hinder effective drug accumulation in the brain. In contrast, the intranasal route leverages the olfactory and trigeminal neural pathways to enable direct drug transport from the nasal cavity to the brain, effectively bypassing the blood-brain barrier and significantly enhancing brain drug bioavailability. This article systematically reviews the research progress of intranasal drug delivery in the treatment of depression-like behaviors, highlighting the technological evolution of various drug-loading modalities, including solutions, gels, nanoparticles, in situ gels, and cell membrane biomimetic carriers, and analyzes their differences in nasal mucosal retention time, mucus penetration ability, and brain-targeting efficiency. Furthermore, it elaborates on the multiple antidepressant mechanisms of intranasal materials, such as regulating neurotransmitter systems (e.g., 5-Hydroxytryptamine, Dopamine, Glutamate), inhibiting neuroinflammation (e.g., microglial activation, inflammatory factor release), enhancing neuroplasticity (e.g., promoting hippocampal neurogenesis and synapse formation), and modulating the gut microbiota-gut-brain axis. Simultaneously, the article integrates data from multiple clinical trials, focusing on evaluating the efficacy and safety of intranasal formulations such as esketamine in treatment-resistant depression, highlighting their advantages of rapid onset and high response rates, and discussing management strategies for adverse reactions such as dose individualization, local irritation, and dissociative symptoms. Addressing current technical bottlenecks, such as uneven drug absorption due to nasal physiological differences, challenges in the large-scale production of nanocarriers, and insufficient long-term safety evidence, the article proposes that future research should focus on the development of intelligent responsive nanocarriers, the construction of multimodal synergistic treatment systems, the design of personalized medication regimens guided by precision medicine, and the coordinated advancement of real-world research and regulatory standards. This review aims to provide comprehensive theoretical support and development directions for the clinical translation of intranasal drug delivery in the field of depression treatment.
- 15 April 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessIntranasal administration in modulating depressive-like behavior and reconstructing treatment paradigms through neuroinflammation and neurotrophic pathways
Intranasal administration, as a non-invasive brain-targeted delivery strategy, offers a promising approach for the treatment of central nervous system disorders, particularly depression. Traditional oral or intravenous drug delivery is often limited by the restrictive permeability of the blood-brain barrier and the hepatic first-pass effect, which hinder effective drug accumulation in the brain. In contrast, the intranasal route leverages the olfactory and trigeminal neural pathways to enable direct drug transport from the nasal cavity to the brain, effectively bypassing the blood-brain barrier and significantly enhancing brain drug bioavailability. This article systematically reviews the research progress of intranasal drug delivery in the treatment of depression-like behaviors, highlighting the technological evolution of various drug-loading modalities, including solutions, gels, nanoparticles, in situ gels, and cell membrane biomimetic carriers, and analyzes their differences in nasal mucosal retention time, mucus penetration ability, and brain-targeting efficiency. Furthermore, it elaborates on the multiple antidepressant mechanisms of intranasal materials, such as regulating neurotransmitter systems (e.g., 5-Hydroxytryptamine, Dopamine, Glutamate), inhibiting neuroinflammation (e.g., microglial activation, inflammatory factor release), enhancing neuroplasticity (e.g., promoting hippocampal neurogenesis and synapse formation), and modulating the gut microbiota-gut-brain axis. Simultaneously, the article integrates data from multiple clinical trials, focusing on evaluating the efficacy and safety of intranasal formulations such as esketamine in treatment-resistant depression, highlighting their advantages of rapid onset and high response rates, and discussing management strategies for adverse reactions such as dose individualization, local irritation, and dissociative symptoms. Addressing current technical bottlenecks, such as uneven drug absorption due to nasal physiological differences, challenges in the large-scale production of nanocarriers, and insufficient long-term safety evidence, the article proposes that future research should focus on the development of intelligent responsive nanocarriers, the construction of multimodal synergistic treatment systems, the design of personalized medication regimens guided by precision medicine, and the coordinated advancement of real-world research and regulatory standards. This review aims to provide comprehensive theoretical support and development directions for the clinical translation of intranasal drug delivery in the field of depression treatment.
- Open Access
- 18 March 2026
- Published by Springer Nature in Cell Regeneration
- Vol. 15 (1) , 12
HUMSCs repair CCl₄-induced chronic liver injury in rats via metabolic regulation
To explore the therapeutic effects of human umbilical cord mesenchymal stem cells (HUMSCs) on repairing CCl₄-induced chronic liver injury in rats via
- 18 March 2026
- Published by Springer Nature in Cell Regeneration
- Vol. 15 (1) , 12
Open AccessHUMSCs repair CCl₄-induced chronic liver injury in rats via metabolic regulation
To explore the therapeutic effects of human umbilical cord mesenchymal stem cells (HUMSCs) on repairing CCl₄-induced chronic liver injury in rats via
- Open Access
- 20 February 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1723051
Muribaculum intestinale in brain-gut axis regulation: promises and limitations for therapeutic applications
In recent years, the role of gut microbiota in the regulation of the gut-brain axis has garnered increasing attention, with Muribaculum intestinale ( M. intestinale ) emerging as a novel member of the gut microbiota, exhibiting unique biological characteristics and potential therapeutic value. This article systematically reviews the regulatory mechanisms of M. intestinale in the gut-brain axis and its associations with various diseases. M. intestinale modulates host neurotransmitter synthesis, immune responses, and intestinal barrier function through metabolites such as short-chain fatty acids, succinate, and 3-hydroxybutyrate, thereby influencing the progression of neurodegenerative disorders, psychiatric diseases, and metabolic diseases. Additionally, this article explores the distribution differences of M. intestinale in the intestines of mice and humans, as well as its susceptibility to external factors like diet, antibiotics, and exercise. Although current research has unveiled the potential roles of M. intestinale , its clinical translation still faces challenges such as technical bottlenecks and individual variability. Future studies should focus on humanized model construction, synthetic biology modifications, and multi-target intervention strategies to achieve precise microbiota-targeted therapies.
- 20 February 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1723051
Open AccessMuribaculum intestinale in brain-gut axis regulation: promises and limitations for therapeutic applications
In recent years, the role of gut microbiota in the regulation of the gut-brain axis has garnered increasing attention, with Muribaculum intestinale ( M. intestinale ) emerging as a novel member of the gut microbiota, exhibiting unique biological characteristics and potential therapeutic value. This article systematically reviews the regulatory mechanisms of M. intestinale in the gut-brain axis and its associations with various diseases. M. intestinale modulates host neurotransmitter synthesis, immune responses, and intestinal barrier function through metabolites such as short-chain fatty acids, succinate, and 3-hydroxybutyrate, thereby influencing the progression of neurodegenerative disorders, psychiatric diseases, and metabolic diseases. Additionally, this article explores the distribution differences of M. intestinale in the intestines of mice and humans, as well as its susceptibility to external factors like diet, antibiotics, and exercise. Although current research has unveiled the potential roles of M. intestinale , its clinical translation still faces challenges such as technical bottlenecks and individual variability. Future studies should focus on humanized model construction, synthetic biology modifications, and multi-target intervention strategies to achieve precise microbiota-targeted therapies.
- Open Access
- 18 February 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17
Gut bacteriome alterations during high altitude exposure: a comprehensive analysis of different species
With the increase of high-altitude sojourn population, more and more studies on hypoxia have been conducted, but the associated changes in gut bacteriome in different hypoxic environments need to be further investigated. Gut bacteriome plays an important role in host adaptation to high-altitude hypoxia, but the contribution of gut bacteriome in high-altitude hypoxia adaptation is still controversial and may be influenced by multiple factors. In this study, we reviewed the changes in diversity and composition of the gut bacteriome of different populations of animals in different highland hypoxic environments, clarified the dynamics of the gut bacteriome during exposure to high altitude, identified the core bacteriome that may contribute to host adaptation to hypoxic environments, and comprehensively considered the effects of multiple factors on the gut bacteriome.
- 18 February 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17
Open AccessGut bacteriome alterations during high altitude exposure: a comprehensive analysis of different species
With the increase of high-altitude sojourn population, more and more studies on hypoxia have been conducted, but the associated changes in gut bacteriome in different hypoxic environments need to be further investigated. Gut bacteriome plays an important role in host adaptation to high-altitude hypoxia, but the contribution of gut bacteriome in high-altitude hypoxia adaptation is still controversial and may be influenced by multiple factors. In this study, we reviewed the changes in diversity and composition of the gut bacteriome of different populations of animals in different highland hypoxic environments, clarified the dynamics of the gut bacteriome during exposure to high altitude, identified the core bacteriome that may contribute to host adaptation to hypoxic environments, and comprehensively considered the effects of multiple factors on the gut bacteriome.
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (2) , 79
Ability of lactylation-related genes to stratify patients with ovarian cancer and predict immunotherapy response
Background: Lactate and lactylation-related genes (LRGs) have demonstrated promising effects in mitigating tumor growth and improving clinical outcomes, but their role in the ovarian cancer (OV) microenvironment and immunotherapy has not been extensively examined. This study aimed to characterize the relationship between LRGs and the outcomes of patients with OV. Methods: We collected bulk RNA-sequencing data from The Cancer Genome Atlas (TCGA) OV dataset via the University of California, Santa Cruz (UCSC) Xena and bulk RNA fragments per kilobase of transcript per million mapped reads (FPKM) sequences of normal ovarian tissues via the Genotype-Tissue Expression (GTEx) project. We then analyzed the relationship of 22 LRGs with programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) and compared the prognosis of patients with different expressions of LRGs in response to anti-PD-1/PD-L1 immunotherapy. We used the hierarchical clustering method to delineate subtypes of patients with OV according to LRG and PD-1 and PD-L1 expression and compared their tumor microenvironment (TME) compositions. A neural network was trained based on LRGs to predict the immunotherapy response in patients with OV, and single-cell RNA (scRNA) analysis was used to clarify the mechanisms underlying the LRGs’ predictive capacity. Meanwhile, a tissue array was used to determine the LRG hub genes’ influence on the prognosis of patients with OV. Results: Most of the LRGs examined were associated with the prognosis of patients with OV undergoing anti-PD-1/PD-L1 immunotherapy. According to the expression of the LRG panel, patients with OV could be clustered in subtypes, with each cluster exhibiting a distinct TME composition and immune-cell ratio. The neural network based on LRG expression could predict the immunotherapy response of patients with OV, with LDHA and LDHB being the potential hub LRGs. Patients with OV and low LDHA expression had better prognosis in terms of disease-free survival (DFS) or overall survival (OS), while patients with OV and high LDHB expression had a longer DFS and OS. Conclusions: The expression of lactylation-related hub genes can be used to stratify patients with OV and predict their response to immunotherapy.
- 1 February 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (2) , 79
Open AccessAbility of lactylation-related genes to stratify patients with ovarian cancer and predict immunotherapy response
Background: Lactate and lactylation-related genes (LRGs) have demonstrated promising effects in mitigating tumor growth and improving clinical outcomes, but their role in the ovarian cancer (OV) microenvironment and immunotherapy has not been extensively examined. This study aimed to characterize the relationship between LRGs and the outcomes of patients with OV. Methods: We collected bulk RNA-sequencing data from The Cancer Genome Atlas (TCGA) OV dataset via the University of California, Santa Cruz (UCSC) Xena and bulk RNA fragments per kilobase of transcript per million mapped reads (FPKM) sequences of normal ovarian tissues via the Genotype-Tissue Expression (GTEx) project. We then analyzed the relationship of 22 LRGs with programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) and compared the prognosis of patients with different expressions of LRGs in response to anti-PD-1/PD-L1 immunotherapy. We used the hierarchical clustering method to delineate subtypes of patients with OV according to LRG and PD-1 and PD-L1 expression and compared their tumor microenvironment (TME) compositions. A neural network was trained based on LRGs to predict the immunotherapy response in patients with OV, and single-cell RNA (scRNA) analysis was used to clarify the mechanisms underlying the LRGs’ predictive capacity. Meanwhile, a tissue array was used to determine the LRG hub genes’ influence on the prognosis of patients with OV. Results: Most of the LRGs examined were associated with the prognosis of patients with OV undergoing anti-PD-1/PD-L1 immunotherapy. According to the expression of the LRG panel, patients with OV could be clustered in subtypes, with each cluster exhibiting a distinct TME composition and immune-cell ratio. The neural network based on LRG expression could predict the immunotherapy response of patients with OV, with LDHA and LDHB being the potential hub LRGs. Patients with OV and low LDHA expression had better prognosis in terms of disease-free survival (DFS) or overall survival (OS), while patients with OV and high LDHB expression had a longer DFS and OS. Conclusions: The expression of lactylation-related hub genes can be used to stratify patients with OV and predict their response to immunotherapy.